Mingfeng Yu completed his PhD in organic chemistry at the University of Sydney under the supervision of Associate Professors Matthew H. Todd and Peter J. Rutledge in 2013. His PhD research entailed the design, synthesis and evaluation of novel scorpionand metal-cyclam complexes appended with biologically-active motifs. He was appointed as a Research Fellow (Medicinal Chemistry) at the University of South Australia upon completion of his PhD. Under the guidance of Professor Shudong Wang, he is currently involved in the discovery and development of novel protein kinase inhibitors for cancer therapy.
About me
Mingfeng Yu completed his PhD in organic chemistry at the University of Sydney under the supervision of Associate Professors Matthew H. Todd and Peter J. Rutledge in 2013. His PhD research entailed the design, synthesis and evaluation of novel scorpionand metal-cyclam complexes appended with biologically-active motifs. He was appointed as a Research Fellow (Medicinal Chemistry) at the University of South Australia upon completion of his PhD. Under the guidance of Professor Shudong Wang, he is currently involved in the discovery and development of novel protein kinase inhibitors for cancer therapy.
About me
Research
Excludes commercial-in-confidence projects.
Discovery of CDK6 inhibitors for treatment of childhood medulloblastoma, Channel 7 Children's Research Foundation of SA, 01/01/2015 - 31/12/2016
New treatment for childhood leukaemia, Channel 7 Children's Research Foundation of SA, 01/01/2016 - 31/12/2016
Research
Research since 2008 is shown below. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
| Year | Output |
|---|---|
| 2018 |
13
9
4
|
| 2018 |
Open access
1
1
|
| 2017 |
4
4
|
| 2017 |
7
7
2
|
| 2017 |
Open access
5
5
|
| 2017 |
Open access
1
1
2
|
| 2017 |
Open access
11
9
|
| 2016 |
7
7
|
| 2016 |
Open access
8
6
|
| 2016 |
3
3
|
| 2016 |
Open access
13
11
2
|
| 2015 |
Open access
|
| 2015 |
12
13
4
|
| 2015 |
6
7
|
| 2015 |
Open access
11
11
|
| 2015 |
16
14
5
|
| 2015 |
16
17
3
|
| 2015 |
31
24
|
| 2014 |
Open access
50
47
5
|
| 2014 |
Open access
34
33
1
|
| 2014 |
Open access
13
11
|
| 2014 |
24
22
|
| 2013 |
Open access
8
8
11
|
| 2013 |
13
12
1
|
| 2011 |
29
29
18
|
| 2010 |
3
3
|
| 2010 |
8
8
|
| 2009 |
|
External engagement & recognition
| Organisation | Country |
|---|---|
| Ain Shams University | EGYPT |
| China University of Geosciences | CHINA |
| CSIRO Australia (Commonwealth Scientific Industrial Research Organisation) | AUSTRALIA |
| Griffith University | AUSTRALIA |
| Max Planck Institute of Colloids and Interfaces | GERMANY |
| National Research Centre | EGYPT |
| Open University | UNITED KINGDOM |
| University of Adelaide | AUSTRALIA |
| University of Nottingham | UNITED KINGDOM |
| University of Oxford | UNITED KINGDOM |
| University of South Australia | AUSTRALIA |
| University of Southampton | UNITED KINGDOM |
| University of Sydney | AUSTRALIA |
| University of Utah | UNITED STATES |
| Yabao Pharmaceutical Group Co., Ltd | CHINA |
External engagement & recognition
| Engagement/recognition | Year |
|---|---|
Chartered MemberRoyal Australian Chemical Institute (RACI) |
2018 |
MemberAmerican Association for Cancer Research (AACR) |
2018 |
MemberAmerican Association for the Advancement of Science (AAAS) |
2018 |
Teaching & student supervision
Supervisions from 2010 shown
| Thesis title | Student status |
|---|---|
| Discovery and development of selective CDK6 inhibitors as anticancer drugs candidates | Current |
| Discovery of novel inhibitors of MAPK-interacting kinases as anti-tumour agents | Current |
| Pharmacodynamics or pharmacokinetics of new anticancer drugs | Current |
| Novel inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents: design, synthesis and evaluation | Completed |
| Protein kinase inhibitors as potential anti-cancer agents: design, synthesis and evaluation | Completed |
